Arrowhead Pharmaceuticals Unveils Obesity Treatment at ADA Conference
Arrowhead Pharmaceuticals Unveils Obesity Treatment at ADA Conference
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually.
納斯達克上市公司Arrowhead Pharmaceuticals, Inc. (NASDAQ：ARWR)今日宣佈其針對肥胖和代謝性疾病的干擾RNA藥物候選藥ARO-INHBE的臨床前數據已在美國糖尿病協會（ADA）第84屆科學會議上（6月21日至24日，於佛羅里達州奧蘭多市及虛擬）公佈。
The preclinical results demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, which has been identified through large genetic studies as a promising target for next generation therapies to address obesity and metabolic diseases. Further, Arrowhead's preclinical research suggests that INHBE knockdown may potentially lead to a suppression in body weight gain, loss of fat mass, and preservation of lean mass. Arrowhead plans to file for regulatory clearance in late 2024 to begin clinical studies of ARO-INHBE.
臨床前結果表明，ARO-INHBE明顯抑制了肝臟中INHBE基因的表達，該基因經過大規模的遺傳研究被確定爲下一代治療肥胖和代謝性疾病的有望靶點。此外，Arrowhead的臨床前研究表明，INHBE的抑制可能潛在地導致體重增加的抑制、脂肪質量的減少和瘦體重的保持。Arrowhead計劃於2024年底申請監管機構批准，開始ARO-INHBE的臨床研究。
"There has been a great deal of progress with new agents to treat obesity and metabolic diseases, but significant loss of lean mass and adverse gastrointestinal events at higher dose levels have necessitated the identification of new therapeutic strategies with novel mechanisms of action," said James Hamilton, M.D., chief of discovery and translational medicine at Arrowhead. "ARO-INHBE directly targets hepatic expression of the INHBE gene. Prior genetic studies have associated loss of function mutations in the INHBE gene with reduced levels of abdominal fat and an improved metabolic profile. Our preclinical data presented at ADA suggest that INHBE reduction with siRNA is a promising new approach to address obesity and metabolic diseases and strongly support advancing ARO-INHBE into clinical trials."
"雖然新藥物治療肥胖和代謝性疾病取得了很大的進展，但在更高劑量下損失大量瘦體重和出現不良的腸胃事件，必須尋找新的治療策略和新的作用機制。"Arrowhead的發現和轉化醫學首席醫生James Hamilton博士說:"ARO-INHBE直接靶向肝臟中的INHBE基因表達。以往的遺傳研究表明INHBE基因缺陷與腹部脂肪的減少和改善代謝水平有關。我們在ADA上展示的臨床前數據表明，使用siRNA減少INHBE表達是解決肥胖和代謝性疾病的有前途的新方法，並且強烈支持將ARO-INHBE推進臨床試驗。"
In pharmacological studies in obese and diabetic mouse models, INHBE siRNA administration resulted in multiple promising findings, including the following:
在肥胖和糖尿病小鼠模型中的藥理研究中，INHBE siRNA的使用帶來了多種有望的發現，包括以下內容：
- 95% reduction in INHBE mRNA expression
- 19% suppression of body weight compared to saline controls
- 26% loss of fat mass
- Preservation of lean mass
- INHBE mRNA表達量的減少達到了95%。
- 與鹽水對照組相比，體重減輕了19%。
- 脂肪質量減少了26%。
- 瘦體重得到了保持。
In addition, co-treatment of tirzepatide with INHBE siRNA allowed for the use of a lower tirzepatide dose without compromising its therapeutic effect. These encouraging results suggest that ARO-INHBE has the potential to be a novel therapeutic for metabolic disease.
此外，聯合使用tirzepatide和INHBE siRNA可在不損害其治療效果的情況下使用更低劑量的tirzepatide。這些令人鼓舞的結果表明，ARO-INHBE有望成爲代謝性疾病的新型治療藥物。